The induction of TA-HEVs which are associated with improved tumour control following combined immune activation (via ICB) and administration of LTβR agonist [12, 13, 35] is closely mirrored in instances of TNF superfamily member 14 (LIGHT) delivery to the tumour microenvironment. The gene discussed is TNFSF14; the disease is neoplasm.